Airsculpt Technologies, INC

AirSculpt Technologies announced second quarter fiscal 2026 results, showing stable same-center case volume but a decline in revenue and Adjusted EBITDA compared to the prior year.

AirSculpt Technologies reported flat first-quarter revenue of $39.4 million, with a 1% increase on a same-center sales basis, and reaffirmed its full-year 2026 financial guidance.

AirSculpt Technologies filed an amendment to correct non-GAAP financial measure errors related to its London facility closure.

AirSculpt Technologies announced its full year 2025 results, showing revenue and case volume declines, but reported sequential improvement in Q4 and positive same-store sales in February 2026.

AirSculpt Technologies announces a delay in its annual report filing, revealing preliminary 2025 revenue of $151.8 million and positive same-store sales in February 2026.

AirSculpt Technologies, Inc. announced the appointment of Mike Doyle, a seasoned multi-center healthcare executive, as its new Non-Executive Chairman of the Board.

AirSculpt Technologies reported a decrease in revenue and an increase in operating expenses for the second quarter of 2026, leading to a net loss, while also addressing material weaknesses in internal controls.

AirSculpt Technologies reports flat Q1 2026 revenue of $39.4 million while continuing to address material weaknesses in internal controls.

AirSculpt Technologies, Inc. reported a significant net loss and revenue decline in Q3 2025, driven by weaker aesthetics industry performance and strategic impairments, while implementing cost reductions and growth initiatives.

AirSculpt Technologies experienced significant revenue and case volume declines in the second quarter of 2025, leading to a net loss, but is implementing strategic initiatives and has raised capital to stabilize performance and reduce debt.

AirSculpt Technologies experienced a revenue decrease in Q1 2025, prompting strategic initiatives to stabilize growth and reduce costs.

AirSculpt Technologies experienced a revenue decrease in the third quarter of 2024, primarily due to weaker performance in the aesthetics and high-end retail sectors.

AirSculpt Technologies, Inc. filed an amendment to its 2025 Annual Report to correct non-GAAP financial measure errors related to its London facility closure.

AirSculpt Technologies reports a 15.8% revenue decline and increased net losses in 2025, alongside a material weakness in internal controls.

AirSculpt Technologies experienced a revenue decline in 2024 and is implementing strategic initiatives, including optimizing marketing, enhancing sales, and expanding financing options, to drive future growth.

AirSculpt Technologies reports a 16.1% increase in revenue for 2023, reaching $195.9 million, driven by expansion and procedure growth.

Director Adam T. Feinstein reports an in-kind distribution of 5,169,820 shares of AirSculpt Technologies common stock.

Airsculpt Technologies, Inc. reports the grant of 100,286 Restricted Stock Units to Director Kenneth Higgins.

AirSculpt Technologies, Inc. Director Thomas Aaron J was granted 100,286 Restricted Stock Units on May 12, 2026, as part of his compensation.

Caroline Chu, a Director at Airsculpt Technologies, Inc., was granted 100,286 Restricted Stock Units on May 12, 2026, vesting on the first anniversary of the grant or the day before the next annual meeting.

Airsculpt Technologies, Inc. reports that Director Jorey Chernett has filed an exit Form 4, detailing the sale of common stock and the expiration of unexercised call options.

Jorey Chernett, a Director at Airsculpt Technologies, Inc., acquired 20,000 shares of common stock.

AirSculpt Technologies, Inc. has issued its proxy statement for the upcoming Annual Meeting of Stockholders scheduled for May 12, 2026, to be held virtually.

AirSculpt Technologies, Inc. has filed a definitive proxy statement with the SEC.

AirSculpt Technologies will hold its annual stockholder meeting virtually on May 7, 2025, to vote on the election of directors and the ratification of its independent auditor.

AirSculpt Technologies, Inc. has filed a definitive proxy statement with the SEC.

AirSculpt Technologies will hold its annual meeting virtually on May 7, 2024, to elect directors and ratify the appointment of its accounting firm.

Aaron Rollins, founder of Airsculpt Technologies, Inc., has disclosed a 23.6% stake and is actively evaluating strategic alternatives for his investment.

A Schedule 13G filing reveals significant beneficial ownership of AirSculpt Technologies, Inc. common stock by entities associated with Vesey Street Capital Partners.

Thrivent Financial for Lutherans and its affiliate TICA have filed an amendment to their Schedule 13G, correcting previous ownership figures and reporting their beneficial ownership as of June 30, 2026.

Dr. Aaron Rollins has filed a Schedule 13G reporting beneficial ownership of 14,721,062 shares of AirSculpt Technologies, Inc.

Parian Ultreia LP has filed a Schedule 13G, reporting beneficial ownership of 6,744,000 shares, representing 9.6% of Airsculpt Technologies, Inc.

Parian Ultreia LP has reported a significant beneficial ownership stake of 9.59% in Airsculpt Technologies, Inc.

Jorey Chernett has increased beneficial ownership in Airsculpt Technologies, Inc. to 10.79% of common stock.